DEEPNOID Inc (315640) Fair Value & Analysis
Healthcare · KR · Market cap 55.5B KRW
Fair value as of: Jun 24, 2026
Analysis
DEEPNOID Inc (315640) currently trades at 1,680 KRW, while our model-based Fair Value estimate is 2,102 KRW — implying the stock looks roughly 25.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
DEEPNOID Inc. provides artificial intelligence solutions for medical and industrial sectors. The company offers various solutions, such as DEEP:NEURO, detects suspected cerebral aneurysm areas in brain through brain MRA images; M4CXR, a CXR reporting solution powered by generative AI; DEEP:CHEST, an AI-based medical image reading assistance solution to detect suspected areas of various diseases in medical images; and DEEP:LUNG, an AI solution that applied to low-dose CT and chest CT images. It also provides SkyMARU:SECURITY, an AI-powered automated X-ray screening solution for enhanced aviation security; DEEP:SECURITY, an AI-powered automated X-ray screening solution for Enhanced Enterprise Security; and DEEP:FACTORY, a deep learning-based machine vision solution developed by Deepnoid for factory automation. The company was founded in 2008 and is based in Seoul, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is DEEPNOID Inc (315640) undervalued?
What is the fair value of 315640?
What is the quality score of 315640?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.